- Home
- TRU vs GMAB Comparison
TRU vs GMAB Comparison
Compare TRU & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRU
- GMAB
- Stock Information
- Founded
- TRU 1968
- GMAB 1999
- Country
- TRU United States
- GMAB Denmark
- Employees
- TRU N/A
- GMAB N/A
- Industry
- TRU Finance: Consumer Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TRU Finance
- GMAB Health Care
- Exchange
- TRU Nasdaq
- GMAB Nasdaq
- Market Cap
- TRU 16.6B
- GMAB 17.4B
- IPO Year
- TRU 2015
- GMAB N/A
- Fundamental
- Price
- TRU $82.60
- GMAB $30.52
- Analyst Decision
- TRU Buy
- GMAB Strong Buy
- Analyst Count
- TRU 12
- GMAB 6
- Target Price
- TRU $104.45
- GMAB $40.40
- AVG Volume (30 Days)
- TRU 2.8M
- GMAB 2.6M
- Earning Date
- TRU 10-23-2025
- GMAB 11-06-2025
- Dividend Yield
- TRU 0.56%
- GMAB N/A
- EPS Growth
- TRU 87.22
- GMAB 132.41
- EPS
- TRU 2.14
- GMAB 25.10
- Revenue
- TRU $4,441,800,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- TRU $9.57
- GMAB $24.92
- Revenue Next Year
- TRU $7.31
- GMAB $15.97
- P/E Ratio
- TRU $38.74
- GMAB $1.21
- Revenue Growth
- TRU 8.30
- GMAB 29.57
- 52 Week Low
- TRU $66.38
- GMAB $17.24
- 52 Week High
- TRU $108.12
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- TRU 53.41
- GMAB 58.11
- Support Level
- TRU $78.34
- GMAB $28.08
- Resistance Level
- TRU $80.80
- GMAB $29.35
- Average True Range (ATR)
- TRU 2.20
- GMAB 0.69
- MACD
- TRU 0.32
- GMAB 0.03
- Stochastic Oscillator
- TRU 51.61
- GMAB 94.57
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.